Clinical care of patients
College continues to work with our College COVID-19 Taskforce to ensure that sensible and appropriate advice is delivered to Fellows and patients in a timely fashion. Fellows are urged to keep abreast of government advice and apply this practically.
The below information has been stepped out in three key areas:
- Triaging of Clinical Care and Patient Categorisation
- Clinical Service Provision
- Patients Taking Immunosuppressive Agents or Biologics
- COVID-19 Dermatology Registries
Triaging of Clinical Care and Patient Categorisation
On 15 May 2020, the Prime Minister announced the reintroduction of hospital elective surgery in three stages, to be reviewed monthly. It is a decision of each jurisdiction to determine the stage, timeline and the level of normal surgical activity.
Guidance has been developed to assist Fellows with decisions around clinical urgency
For guidance on the safe use of laser and energy-based devices, see:
- The Australasian Society of Cosmetic Dermatologists revised statement (26 April 2020): Guidance on the safe use of Laser & Energy Based Devices taking into consideration COVID-19/SARS-CoV-2
- Article published in the AJD (Aug 2020) Guidance on infection control and plume management with Laser and Energy-Based Devices taking into consideration COVID-19 (Sullivan JR et al).
Dermatological manifestations of COVID-19
A factsheet on Dermatological Manifestations of COVID-19 and a visual guide to skin signs associated with COVID-19 including a one page summary have been developed. These aim to inform Fellows of current evidence and prepare for patients presenting with cutaneous eruptions which are secondary to COVID-19 infection.
College has developed guidance on the COVID-19-related management of pernio / chilblains.
Clinical Service Provision
The following information has been developed to assist in your decision making about providing care to patients. Topics include:
- Continuity of care
- Letters and referrals
- Immunosuppressive and biologic medications
- Your role as an advocate
For further information on delivering care by telehealth, visit College’s Telehealth webpages.
The US Centers for Disease Control and Prevention has released interim guidance which aims to advice US clinicians on when it is safe to discontinue transmission-based precautions for patients with confirmed COVID-19, as determined by either a test-based, symptom-based or time-based strategy. Please note that this guidance is subject to frequent review of evidence.
Patients Taking Immunosuppressive Agents or Biologics
For guidance on the management of patients on immunomodulators for cutaneous disease, including biologic agents and new small molecular inhibitors, view the Australian and New Zealand consensus statement published on 9 April 2020 in the Australasian Journal of Dermatology.
College has released two factsheets:
The American Academy of Dermatology has released Guidance on the use of biologic agents during COVID-19 outbreak.
Refer to the Department of Health’s definition of people at risk for serious illness from COVID-19, which includes biologics and most disease-modifying anti-rheumatic drugs (DMARDs).
COVID-19 Dermatology Registries
International Collaboration and Rapid Harmonization across Dermatologic COVID-19 Registries | Journal of the American Academy of Dermatology | Published 17 June 2020
Federal Government Links
Department of Health | COVID-19 Health Alert – daily update
Department of Health | Definition of people at risk for serious illness from COVID-19
MBS Online | COVID-19 Teleheath
Therapeutic Goods Administration | COVID-19: Information on medicines and medical devices
Pharmaceutical Benefits Scheme | Restriction requirement exemptions for some medicines during COVID 19